T cell immunotherapy company developing products for prevention and treatment of infectious diseases (ID) and cancer via T cell induction – spinout from Jenner Institute at University of Oxford. Proprietary ChAdOx (prime) and MVA (boost) technology platform induces and maintains CD8+ T-cells at the maximum levels published to date. Ph1/2 data for HPV and HBV immunotherapies expected 2H20. Encouraging prostate cancer, 5T4 immunotherapeutic data recently released. Ph1/2 NSCLC MAGE-NYESO immunotherapeutic enters clinic in Q1 2021. ChAdOx COVID-19 vaccine out-licensed to Oxford Uni/AstraZeneca with post-pandemic revenue stream. Fast, scalable manufacturing platforms in proprietary cell lines. $150M funding at Jenner Institute and company raised $48M since formation in 2016 from leading investors including GV (formerly Google Ventures), Sequoia China and Oxford Sciences Innovation.
Phase l or ll
Infectious Disease, Oncology
The Schrodinger Building, Heatley Road
The Oxford Science Park
Oxford, OX4 4GE
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.